| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/07/2002 | EP1227859A2 Neurophilin ligands for treating ocular conditions |
| 08/07/2002 | EP1227846A2 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 08/07/2002 | EP1227834A2 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
| 08/07/2002 | EP1227833A1 Plasminogen-like polynucleotides, polypeptides, and antibodies |
| 08/07/2002 | EP1227825A1 Isolation and expansion of human marrow stromal cells |
| 08/07/2002 | EP1227824A1 Transplant/implant device and method for its production |
| 08/07/2002 | EP1227823A2 Methods for inducing (in vivo) proliferation and migration of transplanted progenitor cells in the brain |
| 08/07/2002 | EP1227821A1 Therapeutic compositions and methods of use thereof |
| 08/07/2002 | EP1227813A1 Reverse-turn mimetics and methods relating thereto |
| 08/07/2002 | EP1227798A1 Controlled release hydrocodone formulations |
| 08/07/2002 | EP1227791A2 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 08/07/2002 | EP1227714A1 Method for producing metabolites from plants cultivated in soil-less medium |
| 08/07/2002 | EP1069892B1 Therapeutic system which can be moisture-activated |
| 08/07/2002 | EP1012151B1 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| 08/07/2002 | EP0986562B1 Substituted 1,2,4-triazolo 3,4-a]phthalazine derivatives as gaba alpha 5 ligands |
| 08/07/2002 | EP0971695A4 Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| 08/07/2002 | EP0906276B1 Novel vitamin d analogues |
| 08/07/2002 | EP0801649B1 Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof |
| 08/07/2002 | EP0689434B1 Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof |
| 08/07/2002 | CN1362967A Modulators for beta-amyloid peptide aggregation comprising D-amino acids |
| 08/07/2002 | CN1362954A Sulfamato hydroxamic acid metalloprotease inhibitor |
| 08/07/2002 | CN1362953A Pyrazole compositions useful as inhibitors of ERK |
| 08/07/2002 | CN1362952A 2-arylimino-2,3-dihydothiazoles, and their use thereof as somatostain receptor ligands |
| 08/07/2002 | CN1362947A N-cyanomethylamides as protease inhibitors |
| 08/07/2002 | CN1362881A Inflammatory mediation obtained from atractylodes lancea |
| 08/07/2002 | CN1362879A Patches containing buprenorphine hydrochloride |
| 08/07/2002 | CN1362878A Pharmaceutical preparation containing the active substance heroin and its utilization in a method for treating opiate addiction |
| 08/07/2002 | CN1362877A Method for treating neurodegeneration |
| 08/07/2002 | CN1362409A 2-phenoxy pyrimidine derivative and its use in treating disease |
| 08/07/2002 | CN1362261A Health tonic containing rich lucid ganoderma selenium |
| 08/07/2002 | CN1362241A Nano gastrodia and sharpleaf gambirplant medicine and its preparation |
| 08/07/2002 | CN1362238A Nano analgesic Rhizome corydalis medicine and its preparation |
| 08/07/2002 | CN1362228A Nano heart fire-clearing away bezoar medicine and its preparation |
| 08/07/2002 | CN1362222A Nanometer blood-nourishing and transquilizing medicine and its preparation |
| 08/07/2002 | CN1362182A Nano spleen-invigorating medicine and its preparation |
| 08/07/2002 | CN1362175A Nano Naoliqing medicine and its preparation |
| 08/07/2002 | CN1362168A Nano resurrecting bezoar medicine and its preparation |
| 08/07/2002 | CN1362167A Nano Zhengtian medicine and its preparation |
| 08/07/2002 | CN1362160A Nano Heavn king tonic medicine for mental discomfort and its preparation |
| 08/07/2002 | CN1362132A Nano heart-nourishing biotae medicine and its preparation |
| 08/07/2002 | CN1362128A Nano tranquilizing and brain nourishing medicine and its preparation |
| 08/07/2002 | CN1362105A Nano Angelicae longhui meidcine and its preparation |
| 08/07/2002 | CN1362101A Nano Huolisu medicine for restoring vitality and its preparation |
| 08/07/2002 | CN1362081A Nano tranquilizing cinnabar medicine and its preparation |
| 08/07/2002 | CN1088591C Medicine for curing and preventing upper respiratory infection and stopping-smoking, and its preparing method |
| 08/07/2002 | CN1088587C Topical anti-inflammatory compositions containing piroxican |
| 08/07/2002 | CN1088585C Compound active at novel site on receptor-operated calcium channels use full for treatment of neurological disorders and diseases |
| 08/06/2002 | US6429317 Indane derivatives for antipsychotic compositions |
| 08/06/2002 | US6429313 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 08/06/2002 | US6429303 Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
| 08/06/2002 | US6429223 Modified forms of pharmacologically active agents and uses therefor |
| 08/06/2002 | US6429213 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 08/06/2002 | US6429211 Administering praziquantel to mammals to treat neurological and abortigenical diseases caused by coccidia (such as equine protozoal myeloencephalitis); reduced side effects |
| 08/06/2002 | US6429209 5-ht3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome |
| 08/06/2002 | US6429010 Treating schizophrenia |
| 08/06/2002 | US6428950 Culturing glial cells which express apolipoprotein e at known level, contacting cells with compound to be tested, comparing apolipoprotein e expression of glial cells in contact with compound with apolipoprotein e expression in control culture |
| 08/06/2002 | US6428820 Extracts of Hypericum perforatum and formulations containing them |
| 08/06/2002 | US6428787 TNF inhibitors for the treatment of retinal disorders |
| 08/06/2002 | CA2236707C Fused tropane-derivatives, their preparation and use |
| 08/05/2002 | CA2370355A1 Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration |
| 08/02/2002 | CA2369789A1 Combination treatment for depression |
| 08/02/2002 | CA2369477A1 In vitro assay for testing gabapentinoid activity |
| 08/01/2002 | WO2002059612A2 Animal model and cell-line expressing modified chlorine channel |
| 08/01/2002 | WO2002059604A2 Diagnosis and treatment of multiple sclerosis |
| 08/01/2002 | WO2002059363A2 Method for detecting of prions in a sample |
| 08/01/2002 | WO2002059308A2 Method of diagnosing and treating cartilage disorders |
| 08/01/2002 | WO2002059304A1 Novel g protein-coupled receptor protein and dna thereof |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059286A2 Adenylate cyclases |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059256A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | WO2002059155A2 Modulation of calcium channel activity |
| 08/01/2002 | WO2002059150A2 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 08/01/2002 | WO2002059129A2 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059127A2 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059124A2 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059102A2 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | WO2002059098A1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 08/01/2002 | WO2002059092A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 08/01/2002 | WO2002059088A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | WO2002059083A2 Novel compounds |
| 08/01/2002 | WO2002059082A2 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002059074A1 Benzylamine analogue |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058706A2 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
| 08/01/2002 | WO2002058704A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 08/01/2002 | WO2002058702A1 Urotensin-ii receptor antagonists |
| 08/01/2002 | WO2002058700A1 Methods of administering epothilone analogs for the treatment of cancer |
| 08/01/2002 | WO2002058695A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | WO2002058691A1 Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds |
| 08/01/2002 | WO2002058688A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | WO2002058686A2 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| 08/01/2002 | WO2002058679A2 Antiangiogenic compounds and an assay for inhibitors of cell invasion |
| 08/01/2002 | WO2002058676A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles |
| 08/01/2002 | WO2002058666A2 Process for preparing non-hygroscopic sodium valproate composition |